Long-term data on semaglutide now extends beyond five years for diabetes indications and approximately three years for weight management, with ongoing extension studies continuing to accumulate evidence
Some people on standard maintenance notice tiredness, brain fog or tingling creeping back well before the next injection is due
Cellular Aging & Longevity NAD+ is crucial for activating sirtuins, proteins that regulate aging and inflammation, and promote healthy cell function
Oral peptides can be partially degraded by stomach acid and digestive enzymes for bioavailability concerns, which may limit the amount of active BPC-157 reaching target cells
Standard Cagrilintide Monotherapy Chart CAGRILINTIDE ESCALATION PROTOCOL Week 1-4: [0.6 mg] Tolerance Assessment Week 5-8: [1.2 mg] Efficacy & Safety Review Week 9+: [2.4 mg] Maintenance Monitoring Theoretical Combination Dosing Chart For cagrilintide dosage with tirzepatide , a theoretical combination chart might look like: COMBINATION PROTOCOL (THEORETICAL) TIRZEPATIDE CAGRILINTIDE Week 1-4: 2.5 mg None Week 5-8: 5.0 mg None Week 9-12: 7.5 mg None Week 13-16: 7.5 mg 0.6 mg Introduction Week 17-20: 10 mg 1.2 mg Week 21+: 12.5 mg 2.4 mg Optimization This staged approach minimizes the risk of overwhelming gastrointestinal side effects while allowing for individualized dose optimization
BPC-157 is a cytoprotective and regenerative peptide fragment, while GLP-1 agonists are synthetic hormone mimics designed for metabolic regulation
